Prosecution Insights
Last updated: April 19, 2026

BAYER AKTIENGESELLSCHAFT

3 pending office actions

Portfolio Summary

3
Total Pending OAs
0
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18336769 SPECIFIC ANTIBODY-DRUG-CONJUGATES (ADCS) WITH KSP INHIBITORS AND ANTI-CD123-ANTIBODIES LOCKARD, JON MCCLELLAND 1647 Non-Final OA Jun 16, 2023
17999179 PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE O DELL, DAVID K 1621 Non-Final OA Nov 17, 2022
17979367 NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING SAMALA, JAGADISHWAR RAO 1618 Non-Final OA Nov 02, 2022

Managing BAYER AKTIENGESELLSCHAFT's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month